drugset / Trial / NCT04707664
Sargramostim Use in COVID-19 to Recover Patient Health
Phase 2
Completed
600 enrolled
Partner Therapeutics, Inc.
United States Department of Defense · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.
Timeline
- Start
- 2021-04-27
- Primary completion
- 2021-12-28
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | 250 ug | Inhaled |